Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (61-70 of 301) with videos related to

Pageof 31
Sort By:
Gynecologic Oncology|June 21, 2021
Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysisDavid A Barrington, Paulina J Haight, Cody Calhoun, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 25, 2011
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinomaWarner K Huh, Michael Cibull, Holly H Gallion, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 6, 2019
The association between histological subtype of a first primary endometrial cancer and second cancer riskJennifer Rhoades, Monica Hagan Vetter, James L Fisher, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|August 22, 2009
Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotypingShelly M Seward, Debra L Richardson, Marino E Leon, et al.
Gynecologic Oncology|June 8, 2002
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group studyJohn H Edmonson, John A Blessing, Jonathan A Cosin, et al.
Gynecologic Oncology|October 29, 2008
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformKimberly E Resnick, Hansjuerg Alder, John P Hagan, et al.
Cancer Treatment and Research Communications|August 15, 2018
Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysisCaroline C Billingsley, David E Cohn, Aleia K Crim, et al.
Gynecologic Oncology|March 11, 2006
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancerDavid E Cohn, Sue Valmadre, Kimberly E Resnick, et al.
Cancers|October 16, 2024
Post-Transcriptional Modifications to miRNAs Undergo Widespread Alterations, Creating a Unique Lung Adenocarcinoma IsomiRomeDavid E Cohn, Vanessa G P Souza, Aisling Forder, et al.
Gynecologic Oncology|July 8, 2010
The prognostic significance of the triple negative phenotype in endometrial cancerRajul Kothari, Carl Morrison, Debra Richardson, et al.
Pageof 31

Showing results (61-70 of 301) with videos related to

Sort By:
Pageof 31
Gynecologic Oncology|June 21, 2021
Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysisDavid A Barrington, Paulina J Haight, Cody Calhoun, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 25, 2011
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinomaWarner K Huh, Michael Cibull, Holly H Gallion, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 6, 2019
The association between histological subtype of a first primary endometrial cancer and second cancer riskJennifer Rhoades, Monica Hagan Vetter, James L Fisher, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|August 22, 2009
Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotypingShelly M Seward, Debra L Richardson, Marino E Leon, et al.
Gynecologic Oncology|June 8, 2002
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group studyJohn H Edmonson, John A Blessing, Jonathan A Cosin, et al.
Gynecologic Oncology|October 29, 2008
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformKimberly E Resnick, Hansjuerg Alder, John P Hagan, et al.
Cancer Treatment and Research Communications|August 15, 2018
Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysisCaroline C Billingsley, David E Cohn, Aleia K Crim, et al.
Gynecologic Oncology|March 11, 2006
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancerDavid E Cohn, Sue Valmadre, Kimberly E Resnick, et al.
Cancers|October 16, 2024
Post-Transcriptional Modifications to miRNAs Undergo Widespread Alterations, Creating a Unique Lung Adenocarcinoma IsomiRomeDavid E Cohn, Vanessa G P Souza, Aisling Forder, et al.
Gynecologic Oncology|July 8, 2010
The prognostic significance of the triple negative phenotype in endometrial cancerRajul Kothari, Carl Morrison, Debra Richardson, et al.
Pageof 31